There were 376 press releases posted in the last 24 hours and 169,137 in the last 365 days.

Highlighting Nano Vivere Research on Innovative Ways to Combat Breast Cancer

Nano Vivere

A sea change in the way cancer is analyzed and treated has yielded more than one promising treatment for those diagnosed with the breast cancer.

GUANGZHOU, GUANGDONG, CHINA, June 29, 2018 / -- Nano Vivere (ISIN: CN0024013913), a late stage clinical company, pioneering nanomedicine whose technology is based on proprietary technologies and patents, today announced that Nano Vivere scientists are featured in an article about new targeted therapies to fight breast cancer.
The co-founder and Chief Executive Officer, Dr. Don T. Leung said: “Our research team is testing a family of drugs for positive metastatic breast cancer. The drug is nanoscale Trojan Horse that sneaks into the cancer cell carrying a variety of weapons that stage a multipronged attack on the cancer.”
“The drug plays a dual role. It blocks existing receptors on the surface of the cancer cell, and at the same time plays the role of the vehicle that brings other inhibitors into the cancer cell,” said Dr. Don T. Leung, professor of cardiology and chief of sciences and director of the Nanomedicine Research Center.
“It enters the cytoplasm to the cancer cell. In addition, we put in specific molecular inhibitors of any future receptors, so we burn the candle from both ends. Not only do we block from the outside, we prevent from the inside. There’s one more exciting possibility, which involves including one more weapon inside the Trojan horse: a substance that stimulates the patient’s own immune response to help fight the cancer cells.”
“We genetically prepared a new ‘fusion gene’ that consists of an immune-stimulating protein,” he said. The nano-weapons are in the advanced preclinical stage, which means they are at least a year away from being presented for approval. “With the technology of nanomedicine, we can treat not only primary breast cancer, but we can better treat metastasis,” he continued.
Nanotechnology may be able to cross the blood brain barrier and deliver drugs to stage a multipronged attack on breast cancer, giving more hope to survivors, and taking one more step toward making some late-stage breast cancer a chronic but manageable condition.
If researchers can figure out what molecular switches are turned on, they can turn off the switch.

About Nano Vivere (ISIN: CN0024013913)

Nano Vivere is a late stage clinical company, pioneering nanomedicine that is following its unique path: a new way to treat patients thanks to nanophysics delivered at the cell’s nucleus. The company’s technology is based on proprietary technologies and patents and it operates worldwide from the headquarters based in Guangzhou. Nano Vivere is led by a highly trained and distinguished team of experts who have demonstrated success in the combined fields medicine, biologics, neuroscience, and nanotechnology along with the specialized business development track record requisite for the launch of cutting-edge medical technologies.

Jackline Tang
Nano Vivere
email us here